

# 16° CONGRESSO NAZIONALE AME

## Joint Meeting with AACE Italian Chapter

### Endogenous Hypercortisolism (Cushing from A to Z)



Associazione  
Medici  
Endocrinologi



ITALIAN CHAPTER

## Adrenal surgery: to whom, when, how

Roma, Ergife Palace Hotel  
9-12 Novembre 2017

*Prof. C.P. Lombardi*  
Chief Endocrine Surgery  
C.I.C. – Policlinico "A. Gemelli"

*Istituto di Semeiotica Chirurgica*  
Chairman: Prof. R. Bellantone  
Università Cattolica del Sacro Cuore  
Rome







# to Whom?

## Patients with hypercortisolism due to

ACTH-independent  
cortisol hypersecretion  
(ADRENAL CUSHING'S SYNDROME)



ACTH-dependent  
cortisol hypersecretion





Associazione  
Medici  
Endocrinologi



ITALIAN CHAPTER

# to Whom?

## Towards a universally accepted definition of subclinical Cushing's syndrome – subclinical autonomous hypercortisolism<sup>2</sup>

Warrick J. Inder

Department of Diabetes and Endocrinology, Princess Alexandra Hospital and School of Medicine, the University of Queensland, Brisbane, Australia

2016

The concept of subclinical cortisol excess and importantly its relevance remains a controversial issue in Endocrinology.<sup>1,2</sup> Pre-clinical Cushing's syndrome,<sup>3</sup> subclinical Cushing's syndrome or subclinical hypercortisolism,<sup>2</sup> recently rebadged in the European Society of Endocrinology Guidelines as 'autonomous cortisol secretion',<sup>4</sup> is an example where a universally agreed upon definition (and name) has proven to be elusive. It has even been

Several studies have identified that subclinical Cushing's syndrome is associated with increased morbidity and mortality.<sup>8–12</sup>

Such patients have a higher rate of metabolic complications such as obesity, type 2 diabetes, hypertension and cardiovascular events,<sup>8–10</sup> as well as osteoporosis and vertebral fractures.<sup>13</sup> Con-

tion is.<sup>9</sup> Where patients who have undergone unilateral adrenalectomy have been compared to conservatively managed patients, surgery reduces the rates of diabetes and hypertension and is associated with a reduction in body weight.<sup>14,15</sup> However,

### Therapy of ENDOCRINE DISEASE

#### Improvement of cardiovascular risk factors after adrenalectomy in patients with tumors and subclinical Cushing's syndrome: a systematic review and meta-analysis

Irene Basso<sup>1</sup>, Peter Aarøde<sup>2</sup>, Rachel K. Cowley<sup>3</sup>, Achilles Chouli<sup>4</sup>, Daniel A. Deller<sup>5</sup>, Michael F. Drayna<sup>6</sup>, Ravina Hall<sup>7</sup>, Michael Hensel<sup>8</sup>, Wolfram Hölzl<sup>9</sup>, William F. Young<sup>10</sup>, M. Hassan Ikram<sup>11</sup>

#### Systematic review of surgical treatment of subclinical Cushing's syndrome

M. Basso<sup>1</sup>, M. Cimino<sup>1</sup>, M. Arampati<sup>1</sup>, G. Tucci<sup>1</sup>, M. Hensel<sup>8</sup> and D. Ning<sup>12</sup>  
 1. Department of Internal Medicine, Division of Endocrinology and Metabolism, University of Padova, Italy; 2. Department of Internal Medicine, Division of Endocrinology and Metabolism, University of Padova, Italy; 3. Department of Internal Medicine, Division of Endocrinology and Metabolism, University of Padova, Italy; 4. Department of Internal Medicine, Division of Endocrinology and Metabolism, University of Padova, Italy; 5. Department of Internal Medicine, Division of Endocrinology and Metabolism, University of Padova, Italy; 6. Department of Internal Medicine, Division of Endocrinology and Metabolism, University of Padova, Italy; 7. Department of Internal Medicine, Division of Endocrinology and Metabolism, University of Padova, Italy; 8. Department of Internal Medicine, Division of Endocrinology and Metabolism, University of Padova, Italy; 9. Department of Internal Medicine, Division of Endocrinology and Metabolism, University of Padova, Italy; 10. Department of Internal Medicine, Division of Endocrinology and Metabolism, University of Padova, Italy; 11. Department of Internal Medicine, Division of Endocrinology and Metabolism, University of Padova, Italy; 12. Department of Internal Medicine, Division of Endocrinology and Metabolism, University of Padova, Italy

#### Waiting for change: Symptom resolution after adrenalectomy for Cushing's syndrome

Rebecca S. Siegel MD,<sup>10</sup> Diane M. Elamji MD,<sup>11</sup> Electron Eleftheriou MD,<sup>12</sup> Shikha Luthra,<sup>13</sup> J. Oliver Tyrell MD,<sup>14</sup> and Quyen Trinh MD,<sup>15</sup> *Medical City Dallas, Dallas, TX, USA*



# to Whom?

- ✓ **Subclinical Cushing's Syndrome (SCS)** is defined as a subtle autonomous cortisol hypersecretion without the typical signs and symptoms of hypercortisolism.
- ✓ SCS is reported in 5-48% of patients with **incidentally discovered adrenal masses** and could be frequently encountered in the clinical practice, due to the increasing diagnosis of adrenal incidentaloma.
- ✓ **Controversies** in SCS :



DIAGNOSTIC CRITERIA

MANAGEMENT STRATEGY (observation Vs surgical treatment)

POSTOPERATIVE GLUCOCORTICOID REPLACEMENT THERAPY

## to Whom?

## DIAGNOSTIC CRITERIA

No clinical signs specific to Cushing's syndrome

|                       |  |                                     |   |   |
|-----------------------|--|-------------------------------------|---|---|
| DST 1 mg >1 µg/dL     | + DHEAS <30 µg/dL                            | or ACTH <15 pg/ml                   | or UFC 2xULN                              | or AVS lateralization                     |
| DST 1 mg >1.8 µg/dL   | + LDDST >1.8 µg/dL                           | or Midnight cortisol >7.5 µg/dL     | or ACTH <5 pg/ml                          | or UFC >100 µg/day                        |
| DST 1 mg (no cut-off) | or HDDST (no cut-off)                        | or Low ACTH                         | or High UFC                               | or High serum cortisol                    |
| DST 1 mg >2.5 µg/dL   | + 1 HPA axis alteration                      |                                     |   |   |
| DST 1 mg >3 µg/dL     | + Low ACTH                                   | or Low DHEAS                        | or No cortisol rhythm                     | or Unilateral uptake adrenal scintigraphy |
|                       | or HDDST >1 µg/dL                            |                                     |   |   |
|                       | or UFC >96 µg/day                            | or ACTH <10 pg/ml                   | or Midnight cortisol >5.4 µg/dL           | *   |
| DST 1 mg >3.5 µg/dL   |  |                                     |   |   |
| DST 1 mg >4 µg/dL     | + Low ACTH                                   | or High UFC and/or 17OHC            | or No cortisol rhythm                     |   |
| DST 1 mg >5 µg/dL     | + ACTH <10 pg/ml                             | + UFC >76 µg/day                    |   |   |
|                       | + ACTH <9 pg/ml                              | or UFC >120 µg/day                  | or No cortisol rhythm                     |   |
|                       | + Impaired response to loperamide test 16 mg |                                     |   |   |
|                       | or ACTH <25 pg/ml                            | or No cortisol rhythm               | or Unilateral uptake adrenal scintigraphy |   |
|                       | + HDDST >3 µg/dL                             | + Normalization after adrenalectomy |   |   |
| DST 3 mg >3 µg/dL     | + HDDST >3 µg/dL                             | + UFC post-HDDST ≥ 50% baseline     |   |   |
| DST 4 mg >1.8 µg/dL   | + ACTH <10 pg/ml                             | or UFC >100 µg/day                  | or Cortisol 24.00/8.00 ratio >50%         |   |





Associazione  
Medici  
Endocrinologi



ITALIAN CHAPTER

# to Whom?

## MANAGEMENT STRATEGY

- ✓ Even if subclinical cortisol secretion can determine the metabolic and cardiovascular long-term consequences of Cushing's syndrome (CS), only a minority of patients with SCS will develop an overt CS
- ✓ Endoscopic adrenalectomy may have a beneficial effect on the long term metabolic consequences of subtle cortisol excess, with low morbidity rate



Surgical treatment

Medical treatment and  
observation

## Subclinical Cushing's syndrome: definition and management

M. Terzolo, A. Pia and G. Reimondo

*Internal Medicine I, San Luigi Gonzaga Hospital, University of Turin, Orbassano, Italy*





Fig. 2 Proposed management strategy of subclinical Cushing's syndrome.

**2012**

## Treatment of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline

Lynnette K. Nieman, Beverly M. K. Biller, James W. Findling, M. Hassan Murad, John Newell-Price, Martin O. Savage, and Antoine Tabarin

# When?



**Figure 1.** An algorithm for the treatment of CS. Derived from Nieman LK, Biller BM, Findling JW, et al. The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline. *J Clin Endocrinol Metab*. 2008;93:1526–1540. (17)



Associazione  
Medici  
Endocrinologi



ITALIAN CHAPTER


# When?



Ultima spiaggia?



# When?



**Success:**  
**Timing**  
**Related**

A critical reappraisal of bilateral adrenalectomy for ACTH-dependent Cushing's syndrome  
Martin Reincke et al, EJE 2015, 173, M23-M32



Associazione  
Medici  
Endocrinologi



ITALIAN CHAPTER

# How?

## ENDOSCOPIC ADRENALECTOMY

NEJM



Laparoscopic adrenalectomy for Cushing syndrome and pheochromocytoma



### *“Gold standard”*

- benign adrenal lesions (hypersecretory and no)
- small / medium sized ...

... also proposed in the case of  
large lesions (potentially malignant)

Henry JF, Best Practice & Research 2001  
Gumbs AA, Best Practice & Research 2006  
Brunt LM, Surg Endosc 2006



### Long-term Outcome following Laparoscopic Adrenalectomy for Large Solid Adrenal Cortex Tumors

M. Pecchia, M. S. Pecchia, G. A. Romano, R. Mancuso, H. R. H. Neumann and K. W. Schmid  
Department of Surgery, University of Regensburg, Germany. Department of Endocrinology, Diabetology, Internal Medicine and Department of Radiology, University of Regensburg, Germany. Department of Pathology, University of Regensburg, Germany.

#### Endoscopic treatment of large primary adrenal tumours

Al. G. Maldonado-Perez, J. A. Koenig, K. Mancuso, H. R. H. Neumann and K. W. Schmid  
Department of Surgery, University of Regensburg, Germany. Department of Endocrinology, Diabetology, Internal Medicine and Department of Radiology, University of Regensburg, Germany. Department of Pathology, University of Regensburg, Germany.



#### Role of Laparoscopy in the Management of Adrenal Malignancies

G. A. Romano, M. S. Pecchia, G. A. Pecchia, M. Mancuso, H. R. H. Neumann and K. W. Schmid  
Department of Surgery, University of Regensburg, Germany. Department of Endocrinology, Diabetology, Internal Medicine and Department of Radiology, University of Regensburg, Germany. Department of Pathology, University of Regensburg, Germany.

## ENDOSCOPIC ADRENALECTOMY: techniques

Similar to conventional surgery, several approaches have been described also for the endoscopic adrenalectomy

Henry JF. Best Practice & Research 2001




# How?



## Transperitoneal Lateral Adrenalectomy


The TL approach, the most widespread, is access to a "conventional operating field" ...



The liver and the spleen-pancreatic block

... it allows proper exposure of the adrenal region, facilitated by displacement due to the force of gravity of the structures adjacent to the adrenal gland ...

Henry JF, Best Practice & Research 2001





Associazione  
Medici  
Endocrinologi



ITALIAN CHAPTER



UNIVERSITÀ  
CATTOLICA  
del Sacro Cuore

# Robot-assisted adrenalectomy

U.O.C. Chirurgia Endocrina e Metabolica  
Policlinico "A. Gemelli" - Roma





Associazione  
Medici  
Endocrinologi



ITALIAN CHAPTER



### The Benefits of Robotic Approach:

- vision 3-D,
- best surgeon comfort,
- greater manuality (fine, unnatural movements such as 360 degree instrument rotations that theoretically can improve the peri- and postoperative outcome of surrenectomy).

### Disadvantages:


High Costs (2.3 times higher than TLA)



Associazione  
Medici  
Endocrinologi



# Robot-assisted RIGHT adrenalectomy





Associazione  
Medici  
Endocrinologi




ITALIAN CHAPTER



# How?

## POSTERIOR RETROPERITONEOSCOPIC ADRENALECTOMY




... the Posterior Retroperitoneoscopic Adrenalectomy (PRA) has been adopted by more than **20% of Centers.**

SURGERY

2008

Endoscopic adrenalectomy: Is there an optimal operative approach? Results of a single-center case-control study

Celestino Pier Leonardi, MD,<sup>a</sup> Marco Raffaelli, MD,<sup>a</sup> Corinella De Crea, MD,<sup>a</sup> Liliana Sellazzi, MD,<sup>b</sup> Valter Perilli, MD,<sup>a</sup> Maria Teresa Cazzato, MD,<sup>a</sup> and Rocco Bellantone, MD,<sup>a</sup> Rome, Italy



Walz M. Surgery 2006  
Gumbs AA, Gagner M. Best Practice & Research 2006



Associazione  
Medici  
Endocrinologi



ITALIAN CHAPTER

# Posterior Retroperitoneoscopic Adrenalectomy

Although PRA has been proposed also for large adrenal tumors...

Original article

## Endoscopic treatment of large primary adrenal tumours

M. K. Walz<sup>1</sup>, S. Petersenn<sup>3</sup>, J. A. Koch<sup>2</sup>, K. Mann<sup>3</sup>, H. P. H. Neumann<sup>5</sup> and K. W. Schmid<sup>4</sup>

<sup>1</sup>Department of Surgery and Centre of Minimally Invasive Surgery and <sup>2</sup>Department of Radiology, Kliniken Essen-Mitte, and <sup>3</sup>Department of Endocrinology and <sup>4</sup>Institute of Pathology, University of Duisburg-Essen, Essen, and <sup>5</sup>Medical Department IV, University of Freiburg, Freiburg, Germany

Correspondence to: Professor M. K. Walz, Department of Surgery and Centre of Minimally Invasive Surgery, Kliniken Essen-Mitte, Henriettenstrasse 92, D-45116 Essen, Germany (e-mail: m.k.walz@kliniken-essen-mitte.de)



Large tumor size is indicated as the main limitation of PRA, mainly because of the small working space.







Associazione  
Medici  
Endocrinologi



ITALIAN CHAPTER

# Posterior Retroperitoneoscopic Adrenalectomy



## Advantages:

- Direct access to adrenal gland
- Excellent control of adrenal vein
- **Extraperitoneal approach**
- The best approach in case of previous surgery
- **Bilateral adrenalectomy**

Walz M, *Surgery* 2006  
Lombardi CP, *Surgery* 2008  
Perrier ND, *Ann Surg* 2008  
Lombardi CP, *Surgery* 2011  
Lee CR, *Ann Surg Oncol* 2013  
Raffaelli M, *World J Surg* 2014

## Disadvantages:

*... lack of anatomical landmarks ?!*

- Limited exposure
- Contraindicated in case of >6-7 cm lesions







Associazione  
Medici  
Endocrinologi



ITALIAN CHAPTER

# Posterior Retroperitoneoscopic Adrenalectomy

The patient is placed in prone position



Walz et al





Associazione  
Medici  
Endocrinologi



ITALIAN CHAPTER

# Posterior Retroperitoneoscopic RIGHT Adrenalectomy







Associazione  
Medici  
Endocrinologi



ITALIAN CHAPTER

# Posterior Retroperitoneoscopic LEFT Adrenalectomy



# Posterior retroperitoneoscopic adrenalectomy


## "Tricks and Traps"

A carbon dioxide  
pneumoretroperitoneum  
is established at 20-25  
mmHg



High pressures facilitate the opening of  
the retroperitoneal space

Better control of small bleeding



- Complete mobilization of the upper renal pole greatly facilitates retroperitoneoscopic dissection of the adrenal gland;
- Careful dissection clearly identifies the main vessels.

# Systematic review and meta-analysis of retroperitoneoscopic versus laparoscopic adrenalectomy

V. A. Constantinides, I. Christakis, P. Touska and F. F. Palazzi *British Journal of Surgery* 2012; 99: 1639–1648



22 Published Articles

1257  
TLA      Vs      238  
PostRA      471  
LatRA

|                                 | No. of studies | No. of patients | Odds ratio or SMD     | P     | $\chi^2$ | Heterogeneity<br>P |
|---------------------------------|----------------|-----------------|-----------------------|-------|----------|--------------------|
| <b>Operative parameters</b>     |                |                 |                       |       |          |                    |
| Duration of operation (min)     | 7              | 444             | -0.23 (-1.43, 0.98)*  | 0.711 | 176.67   | < 0.001            |
| Operative blood loss (ml)       | 4              | 271             | -0.33 (-1.40, 0.74)*  | 0.552 | 41.35    | < 0.001            |
| Intraoperative bleeding         | 4              | 301             | 0.83 (0.17, 4.14)     | 0.825 | 3.11     | 0.373              |
| <b>Postoperative parameters</b> |                |                 |                       |       |          |                    |
| Time to oral intake (days)      | 2              | 66              | 0.07 (-0.42, 0.56)*   | 0.789 | 1.38     | 0.242              |
| Time to full ambulation (days)  | 2              | 66              | 0.07 (-0.41, 0.56)*   | 0.761 | 1.35     | 0.251              |
| Length of hospital stay (days)  | 5              | 269             | -1.45 (-2.76, -0.14)* | 0.034 | 85.11    | < 0.001            |
| Overall complications           | 3              | 138             | 1.58 (0.40, 6.23)     | 0.510 | 1.49     | 0.478              |
| Pneumothorax/haemothorax        | 2              | 62              | 0.60 (0.07, 5.22)     | 0.643 | 0.30     | 0.589              |
| Neuralgia                       | 3              | 272             | 4.88 (0.80, 29.76)    | 0.091 | 0.27     | 0.875              |
| Death                           | 2              | 196             | 0.27 (0.03, 2.48)     | 0.226 | 0.30     | 0.587              |

There were no differences in duration of operation, blood loss, time to ambulation and oral intake, or complication rates between techniques

**"PostRA/LatRA overall has equivalent outcomes to TLA...  
...but may be associated with a shorter hospital stay"**

## Simultaneous bilateral posterior retroperitoneoscopic adrenalectomy



*...The posterior approach exposes  
both the adrenal glands at the  
same time*



## Bilateral Adrenalectomy



# Bilateral Adrenalectomy

| Author (year)             | Diagnosis (n)                        | Approach                                    | Operative time (min) | Conversion | Blood loss (ml) | Hospital stay (days) | Postoperative morbidity & mortality (n)                                     |
|---------------------------|--------------------------------------|---|----------------------|------------|-----------------|----------------------|---|
| Fernandez-Cruz et al. [3] | CS (4)<br>Pheo (1)                   | Transperitoneal                             | 285                  | None       | 475             | 6                    | None  |
| Chapuis et al. [15]       | CS (10)                              | Transperitoneal                             | 295                  | None       | NA              | 6                    | Subphrenic abscess (1)  |
| Acosta et al. [2]         | CS (17)                              | Transperitoneal                             | 360                  | 1          | NA              | 6                    | Hypoglycemia (1)<br>Back pain (1)<br>Death from gastro-intestinal bleed (1) |
| Shichman et al. [16]      | CS (5)                               | Transperitoneal                             | 403                  | None       | 190             | 3.8                  | None  |
| Bonjer et al. [17]        | CS (13)<br>Pheo (3)                  | Retroperitoneal                             | 214                  | 1          | 121             | 5                    | Hematoma (1), UTI (1), Death from sepsis (1)                                |
| Lezoche et al. [18]       | CS (5)<br>Pheo (1)                   | Transperitoneal                             | 220                  | 1          | NA              | NA                   | Death from colon injury (1)   |
| Vella et al. [19]         | CS (19)                              | Transperitoneal                             | 252                  | 3          | NA              | 2.7                  | DVT (1)   |
| Hasan et al. [20]         | CS (3)<br>Pheo (3)<br>Metastases (1) | Transperitoneal                             | 308                  | None       | 138             | 5.1                  | None  |
| Hawn et al. [21]          | CS (18)                              | Transperitoneal                             | 296                  | None       | 218             | 3                    | Hemorrhage (1)<br>Pancreatitis (1)  |
| Porpiglia et al. [1]      | CS (13)                              | Transperitoneal                             | 234                  | 2          | 340             | 5.7                  | Wound infection (1)   |
| Jager et al. [22]         | CS (16)<br>Pheo (2)                  | Transperitoneal (16)<br>Retroperitoneal (2) | 289                  | None       | 125             | 7                    | Death from pulmonary embolus (1)  |
| Mikhail et al. [23]       | CS (5)                               | Transperitoneal                             | 295                  | None       | 200             | 7                    | DVT (2)<br>Wound infection (1)<br>UTI (2)                                   |
| Current series 2007       | CS (25)<br>Pheo (5)                  | Transperitoneal                             | 290                  | None       | 81              | 3.5                  | Addisonian crisis (1)<br>Pneumonia (1)<br>Wound infection (1)               |
| Total                     | Mean operative time <b>288</b>       |   | 4.7%                 | Mean 236   | Mean 5.5        |                      |   |

CS, Cushing's syndrome; Pheo, pheochromocytoma; NA, not available; UTI, urinary tract infection; DVT, deep vein thrombosis.

**13% Complications**

**2.4% Mortality**



## Bilateral Adrenalectomy

"Even if TLA has been successfully performed also in the case of bilateral adrenalectomy, it is associated with significantly longer operative time when compared with *conventional technique*, because of the need to repositioning the patients".

Gagner M, Best Practice & Research 2006

|                         | <b>TLA</b> | <b>Open</b> |
|-------------------------|------------|-------------|
| Operative time (min)    | 234'       | 181'        |
| Porpiglia et al. (2004) |            |             |





Associazione  
Medici  
Endocrinologi



ITALIAN CHAPTER


# Bilateral Adrenalectomy

**ACTH-dependent Cushing syndrome: The potential benefits of simultaneous bilateral posterior retroperitoneoscopic adrenalectomy.**  
Lombardi CP, Raffaelli M, De Crea C, Bellantone R, Fusco A, Bianchi A, Pontecorvi A, De Marinis


**Synchronous Bilateral Adrenalectomy for Cushing's Syndrome: Laparoscopic Versus Posterior Retroperitoneoscopic Versus Robotic Approach**

Raffaelli M, Brunaud L, De Crea C, Hoche G, Oragano L, Bresler L, Bellantone R, Lombardi CP

2007 → 2014



LEFT ADRENALECTOMY Equipe



RIGHT ADRENALECTOMY Equipe

# Synchronous Bilateral Adrenalectomy for Cushing's Syndrome: Laparoscopic Versus Posterior Retroperitoneoscopic Versus Robotic Approach

Marco Raffaelli · Laurent Brunaud · Carmela De Crea · Guillaume Hoche · Luigi Oragano · Laurent Bresler · Rocco Bellantone · Celestino P. Lombardi

Operative time was significantly shorter in the PR-BilA group, because it eliminates the need to repositioning the patient. The number of drains and the length of hospital stay were reduced after RA-BilA, but this was likely related to different management protocols in different settings.

| Variables                                | RA-BilA                      | PR-BilA                        | TL-BilA                        | P value             |
|--|------------------------------|--------------------------------|--------------------------------|---------------------|
| Patients                                 | 13                           | 11                             | 5                              |                     |
| Age (years) <sup>a</sup>                 | 42.8 ± 13.6 (18–63)          | 41.2 ± 13.1 (18–62)            | 46.8 ± 19.9 (15–67)            | 0.777               |
| Gender (male/female)                     | 2/11                         | 2/9                            | 2/3                            |                     |
| Preoperative diagnosis                   |                              |                                |                                | 0.591               |
| Cushing's disease                        | 7 (43.7 %) <sup>b</sup>      | 8 (72.7 %) <sup>f</sup>        | 2 (40.0 %) <sup>d</sup>        |                     |
| Ectopic ACTH secretion                   | 4 (25 %) <sup>b</sup>        | 3 (27.3 %) <sup>f</sup>        | 2 (40.0 %) <sup>d</sup>        |                     |
| ACTH-independent Cushing                 | 2 (12.5 %) <sup>b</sup>      | 0 (0.0 %) <sup>c</sup>         | 1 (20.0 %) <sup>d</sup>        |                     |
| Previous abdominal surgery               | 3 (25.0 %) <sup>b</sup>      | 3 (27.2 %) <sup>f</sup>        | 2 (40.0 %) <sup>d</sup>        | 0.772               |
| BMI (kg/m <sup>2</sup> ) <sup>a</sup>    | 30.2 ± 6.5 (18.5–46.0)       | 27.9 ± 4.6 (22.5–36.7)         | 31.9 ± 4.8 (25.4–36.6)         | 0.379               |
| ASA score                                |                              |                                |                                |                     |
| I/II/III/IV/V                            | 0/10/3/0/0                   | 0/8/3/0/0                      | 0/4/1/0/0                      | 0.945               |
| Operative time (min) <sup>a</sup>        | 221.5 ± 42.2 (155–285)       | 157.4 ± 54.6 (85–240)          | 256.0 ± 43.4 (210–300)         | <0.001              |
| Conversion to open approach              | 0                            | 0 <sup>f</sup>                 | 0                              | NS                  |
| Blood transfusion                        | 0                            | 1 (9.1 %) <sup>c</sup>         | 1 (20.0 %) <sup>d</sup>        | 0.304               |
| Drain yes/no                             | 4/9                          | 11/0                           | 5/0                            | <0.001              |
| Intraoperative complications             | 3 (18.7 %) <sup>b</sup>      | 1 (9.1 %) <sup>c</sup>         | 0                              | 0.578               |
| Postoperative complications              | 2 (12.5 %) <sup>b</sup>      | 3 (27.2 %) <sup>f</sup>        | 0                              | 0.397               |
| Clavien-Dindo classification             | IIIa, IV                     | I, II, III                     |                                |                     |
| Time to first flatus (days) <sup>a</sup> | 1.8 ± 0.6 (1–3)              | 1.6 ± 0.5 (1–2)                | 2.3 ± 1.2 (1–3)                | 0.195               |
| Hospital stay (days) <sup>a</sup>        | 4.4 ± 1.7 (2–8) <sup>f</sup> | 10.8 ± 3.7 (5–18) <sup>f</sup> | 12.0 ± 5.7 (8–22) <sup>f</sup> | <0.001 <sup>f</sup> |
| Follow-up (months) <sup>a</sup>          | 18.8 ± 16.4 (2–48)           | 33.5 ± 22.4 (8–72)             | 46.8 ± 43.6 (2–98)             | 0.094               |
| Disease-related death                    | 0 (0 %) <sup>b</sup>         | 0 (0 %) <sup>f</sup>           | 0 (0 %) <sup>d</sup>           | NS                  |
| Death for unrelated causes               | 0 (0 %) <sup>b</sup>         | 1 (9.1 %) <sup>c</sup>         | 1 (20.0 %) <sup>d</sup>        | 0.304               |



Associazione  
Medici  
Endocrinologi




ITALIAN CHAPTER

# 615 ADRENALECTOMIES

U.O.C. Chirurgia Generale ed Endocrina  
Policlinico "A. Gemelli" – Roma

July 1997- October 2017





Associazione  
Medici  
Endocrinologi




ITALIAN CHAPTER

# 615 ADRENALECTOMIES

U.O.C. Chirurgia Generale ed Endocrina  
Policlinico "A. Gemelli" – Roma

July 1997- October 2017





Associazione  
Medici  
Endocrinologi



ITALIAN CHAPTER



*Thanks for your attention!*